Genmab: multiple myeloma drug shows benefit

(CercleFinance.com) - A cancer drug developed by Denmark's Genmab has met its primary endpoint in a Phase 3 study, the company said late on Wednesday.


Genmab said the second part of a study on daratumumab monotherapy as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant showed a 47% reduction in the risk of disease progression or death in patients treated with the drug.

Based on these results, an independent data monitoring committee recommended to unblind the study results, the biotech firm added.

J&J's Janssen (which licensed daratumumab from Genmab in 2012) said it plans to discuss the potential for a regulatory submission for this indication with health authorities.

Genmab shares were pretty flat (-0.2%) after these announcements on Thursday morning.

Copyright (c) 2020 CercleFinance.com. All rights reserved.